Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. Roloff GW, Aldoss I, Kopmar NE, Lin C, et al. J Clin Oncol 2025;43:558-566.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Roloff GW, Aldoss I, Kopmar NE, Lin C, et al. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol 2025;43:558-566.
PMID: 39418622